Silence Therapeutics plc (SLN)
NASDAQ: SLN · IEX Real-Time Price · USD
22.30
-0.20 (-0.89%)
Apr 23, 2024, 12:19 PM EDT - Market open

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.

It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders.

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.

Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics plc
Silence Therapeutics logo
Country United Kingdom
Industry Biotechnology
Sector Healthcare
Employees 109
CEO Craig A. Tooman M.B.A.

Contact Details

Address:
72 Hammersmith Road
London, X0 W14 8TH
United Kingdom
Phone 44-0-20-3457 6900
Website silence-therapeutics.com

Stock Details

Ticker Symbol SLN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001479615
CUSIP Number 82686Q101
ISIN Number US82686Q1013
SIC Code 2834

Key Executives

Name Position
Craig A. Tooman M.B.A. President, Chief Executive Officer and Executive Director
Rhonda L. Hellums Chief Financial Officer and Secretary
Dr. Steven J. Romano M.D. Head of Research and Development
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer
Gem Gokmen Hopkins Head of IR and Corporate Communications
Dr. Barbara A. Ruskin J.D., Ph.D. Senior Vice President and Chief Intellectual Property and Innovation Officer
Dr. Eric Floyd M.B.A., M.S., Ph.D. Senior Vice President of Regulatory Affairs and Quality Assurance
J.P. Gabriel Chief Technical Operations Officer
Curtis Rambaran M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 15, 2024 6-K Report of foreign issuer
Mar 27, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 13, 2024 20-F Annual and transition report of foreign private issuers
Mar 13, 2024 6-K Report of foreign issuer
Feb 23, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 6-K Report of foreign issuer